Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer

Source : https://clincancerres.aacrjournals.org/content/early/2021/02/05/1078-0432.CCR-20-4023.abstract

Purpose: KRAS mutations are identified in ~30% of patients with NSCLC. Novel direct inhibitors of KRAS G12C have shown activity in early phase clinical trials. We hypothesized patients with KRAS G12C mutations may have distinct clinical characteristics and responses to therapies.